HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunogenic cancer cell death: a key-lock paradigm.

Abstract
Physiological cell death, which occurs as a continuous byproduct of cellular turnover, is non-immunogenic or even tolerogenic, thereby avoiding autoimmunity. By contrast, cancer cell death elicited by radiotherapy and some chemotherapeutic agents such as anthracyclines is immunogenic. Recent data suggest that innate and cognate immune responses elicited by such anti-cancer agents are required for an optimal therapeutic outcome, underscoring the clinical relevance of immunogenic cell death. Here we discuss the concept that immunogenic death involves changes in the composition of the cell surface, as well as the release of soluble immunogenic signals that occur in a defined temporal sequence. This 'key' then operates on a series of receptors expressed by dendritic cells (DC, the 'lock') to allow for the presentation of tumor antigens to T cells and for the initiation of a productive immune response. Immunogenic cell death is characterized by the early cell surface exposure of chaperones including calreticulin and/or heat shock proteins, which determine the uptake of tumor antigens and/or affect DC maturation. Moreover, the late release of High mobility group box 1 (HMGB1), which acts on toll-like receptor 4 (TLR4), is required for optimal presentation of antigens from dying tumor cells. Nonetheless, numerous details on the molecular events that define immunogenicity remain to be defined, both at the level of the dying cancer cells and at the level of the responding innate effectors.
AuthorsAntoine Tesniere, Lionel Apetoh, Francois Ghiringhelli, Nicholas Joza, Theocharis Panaretakis, Oliver Kepp, Frederic Schlemmer, Laurence Zitvogel, Guido Kroemer
JournalCurrent opinion in immunology (Curr Opin Immunol) Vol. 20 Issue 5 Pg. 504-11 (Oct 2008) ISSN: 0952-7915 [Print] England
PMID18573340 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antigens, Neoplasm
  • Calreticulin
  • HMGB1 Protein
  • Heat-Shock Proteins
  • TLR4 protein, human
  • Toll-Like Receptor 4
Topics
  • Animals
  • Antigens, Neoplasm (immunology, metabolism)
  • Apoptosis (immunology)
  • Calreticulin (immunology, metabolism)
  • Dendritic Cells (immunology, metabolism)
  • HMGB1 Protein (immunology, metabolism)
  • Heat-Shock Proteins (immunology, metabolism)
  • Humans
  • Lymphocyte Activation (immunology)
  • Mice
  • Neoplasms (immunology, pathology)
  • T-Lymphocytes (immunology, metabolism)
  • Toll-Like Receptor 4 (immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: